Figure 2: Trial profile.
Categories for participants who discontinued study treatment, are no longer ongoing in study, or who received subsequent anticancer therapy are not exclusive, and participants might be included in more than one of these categories. ITT=intention-to-treat. *One participant discontinued study treatment because their second lesion did not respond to TACE and one participant discontinued study treatment due to deteriorating performance status. †One participant discontinued study treatment due to COVID-19 pandemic-related logistics and one participant discontinued study treatment before receiving placebo for bevacizumab due to clinical judgement after COVID-19 infection resolution. ‡Reasons for discontinuation of study treatment only include reasons for durvalumab discontinuation. §As assessed by the investigator.